243 reports of this reaction
1.8% of all METHIMAZOLE reports
#11 most reported adverse reaction
AGRANULOCYTOSIS is the #11 most commonly reported adverse reaction for METHIMAZOLE, manufactured by AiPing Pharmaceutical, Inc.. There are 243 FDA adverse event reports linking METHIMAZOLE to AGRANULOCYTOSIS. This represents approximately 1.8% of all 13,542 adverse event reports for this drug.
Patients taking METHIMAZOLE who experience agranulocytosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
AGRANULOCYTOSIS is a less commonly reported adverse event for METHIMAZOLE, but still significant enough to appear in the safety profile.
In addition to agranulocytosis, the following adverse reactions have been reported for METHIMAZOLE:
The following drugs have also been linked to agranulocytosis in FDA adverse event reports:
AGRANULOCYTOSIS has been reported as an adverse event in 243 FDA reports for METHIMAZOLE. This does not prove causation, but indicates an association observed in post-market surveillance data.
AGRANULOCYTOSIS accounts for approximately 1.8% of all adverse event reports for METHIMAZOLE, making it a notable side effect.
If you experience agranulocytosis while taking METHIMAZOLE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.